

Research

## Original Investigation

# Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders

## Baseline Results From the RAISE-ETP Study

Christoph U. Correll, MD; Delbert G. Robinson, MD; Nina R. Schooler, PhD; Mary F. Brunette, MD; Kim T. Mueser, PhD; Robert A. Rosenheck, MD; Patricia Marcy, BSN; Jean Addington, PhD; Sue E. Estroff, PhD; James Robinson, MEd; David L. Penn, PhD; Susan Azrin, PhD; Amy Goldstein, PhD; Joanne Severe, MS; Robert Heinessen, PhD; John M. Kane, MD

**IMPORTANCE** The fact that individuals with schizophrenia have high cardiovascular morbidity and mortality is well established. However, risk status and moderators or mediators in the earliest stages of illness are less clear.

**OBJECTIVE** To assess cardiometabolic risk in first-episode schizophrenia spectrum disorders (FES) and its relationship to illness duration, antipsychotic treatment duration and type, sex, and race/ethnicity.

**DESIGN, SETTING, AND PARTICIPANTS** Baseline results of the Recovery After an Initial Schizophrenia Episode (RAISE) study, collected between July 22, 2010, and July 5, 2012, from 34 community mental health facilities without major research, teaching, or clinical FES programs. Patients were aged 15 to 40 years, had research-confirmed diagnoses of FES, and had less than 6 months of lifetime antipsychotic treatment.


**EXPOSURE** Prebaseline antipsychotic treatment was based on the community clinician's and/or patient's decision.

**MAIN OUTCOMES AND MEASURES** Body composition and fasting lipid, glucose, and insulin parameters.

**RESULTS** In 394 of 404 patients with cardiometabolic data (mean [SD] age, 23.6 [5.0] years; mean [SD] lifetime antipsychotic treatment, 47.3 [46.1] days), 48.3% were obese or overweight, 50.8% smoked, 56.5% had dyslipidemia, 39.9% had prehypertension, 10.0% had hypertension, and 13.2% had metabolic syndrome. Prediabetes (glucose based, 4.0%; hemoglobin A<sub>1c</sub> based, 15.4%) and diabetes (glucose based, 3.0%; hemoglobin A<sub>1c</sub> based, 2.9%) were less frequent. Total psychiatric illness duration correlated significantly with higher body mass index, fat mass, fat percentage, and waist circumference (all  $P < .01$ ) but not elevated metabolic parameters (except triglycerides to HDL-C ratio [ $P = .04$ ]). Conversely, antipsychotic treatment duration correlated significantly with higher non-HDL-C, triglycerides, and triglycerides to HDL-C ratio and lower HDL-C and systolic blood pressure (all  $P \leq .01$ ). Olanzapine was significantly associated with higher triglycerides, insulin, and insulin resistance, whereas quetiapine fumarate was associated with significantly higher triglycerides to HDL-C ratio (all  $P \leq .02$ ).

**CONCLUSIONS AND RELEVANCE** In patients with FES, cardiometabolic risk factors and abnormalities are present early in the illness and likely related to the underlying illness, unhealthy lifestyle, and antipsychotic medications, which interact with each other. Prevention of and early interventions for psychiatric illness and treatment with lower-risk agents, routine antipsychotic adverse effect monitoring, and smoking cessation interventions are needed from the earliest illness phases.

*JAMA Psychiatry*. 2014;71(12):1350-1363. doi:10.1001/jamapsychiatry.2014.1314  
Published online October 8, 2014.

 Supplemental content at [jamapsychiatry.com](https://jamapsychiatry.com)

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Christoph U. Correll, MD, Division of Psychiatry Research, North Shore-LIJ Health System, The Zucker Hillside Hospital, 75-59 263rd St, Glen Oaks, NY 11004 (ccorrell@lij.edu).

Schizophrenia spectrum disorders are associated with 2- to 3-fold excess mortality<sup>1-3</sup> and a 10- to 30-year gap in life expectancy<sup>4-7</sup> that has been widening<sup>2,8-11</sup> compared with the general population. Whereas secondary and tertiary prevention has improved in the general population,<sup>8,12,13</sup> people with schizophrenia receive inadequate care for physical illnesses<sup>12,14-17</sup> despite available guidelines.<sup>18</sup> The vast majority of this group's premature mortality is related to cardiovascular illness and obesity-related cancers.<sup>4,7,11,13,19</sup> Reasons for the excess cardiovascular risk are complex, involving schizophrenia-related factors, poverty, unhealthy lifestyle, suboptimal medical monitoring and care, and adverse effects of treatment.<sup>13,20,21</sup>

Because cardiovascular risk factors may develop quickly<sup>22-24</sup> and overweight or obesity can lead to diabetes mellitus and coronary heart disease risk,<sup>25</sup> even if weight is lost later in life,<sup>26</sup> patients with first-episode schizophrenia spectrum disorders (FES) require attention to both psychiatric and medical health. Although antipsychotics are the cornerstone of FES treatment<sup>27</sup> and reduce psychiatric symptoms and overall mortality,<sup>28,29</sup> they can cause cardiometabolic adverse effects<sup>20,21</sup> that should be prevented.<sup>30</sup> Unfortunately, little is known about the trajectory of cardiometabolic risk as patients progress through their illness. Further, FES data are scarce and largely limited to samples assessed in controlled trials and/or academic settings.

To better characterize the cardiometabolic health of patients with FES and its relationship to sex, race/ethnicity, illness duration, and antipsychotic treatment, we report baseline data from patients with FES enrolled in a prospective treatment study at 34 real-world community mental health clinics across the United States.

## Methods

As part of the National Institute of Mental Health-funded Recovery After an Initial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) study, we examined the cardiovascular health of individuals with FES. Baseline data were collected from July 22, 2010, through July 5, 2012. The study was approved by the North Shore-LIJ Health System Institutional Review Board and/or local site institutional review boards. Adults provided written informed consent; patients younger than 18 years provided written assent, with legal guardians providing written informed consent.

### Study Design

The RAISE-ETP study is a cluster-randomized comparison of NAVIGATE, an integrated program of medication treatment guided by a decision support system, individual psychotherapy, family psychoeducation, and supported employment or education vs community care determined by the clinician's or patient's choice. Sites included 34 community mental health centers without major research, teaching, or clinical first-episode programs, located in diverse communities ranging from semirural to large urban (eAppendix 1 in the Supplement).

### Patients and Treatment

The following were inclusion criteria for the patients: (1) being aged 15 to 40 years (1 patient was aged 51 years; a protocol exception was filed); (2) being diagnosed as having schizophrenia, schizophreniform disorder, schizoaffective disorder, psychotic disorder not otherwise specified, or brief psychotic disorder; (3) having less than 6 months of cumulative antipsychotic use (defining *first episode*); and (4) being proficient in English. The following were exclusion criteria: (1) being diagnosed as having bipolar disorder, major depressive disorder with psychosis, substance-induced psychotic disorder, or psychotic disorder due to a general medical condition; (2) having current neurological disorders affecting diagnosis or prognosis; and (3) having clinically significant head trauma or another serious medical condition. The inclusion and exclusion of patients are shown in **Figure 1**. Any treatment received prior to study participation or assessment was based on the community clinician's and/or patient's choice.

### Assessment

Assessments pertinent herein documented prescribed medication, demographic, psychosocial, illness duration, medical and substance use information (based on site personnel interview of the patient or informants with or without medical record review). Race and ethnicity were coded based on patient or informant information and assessed because these variables have been associated with cardiovascular risk factors and illness in the general population. Diagnoses were determined using the Structured Clinical Interview for *DSM-IV* Axis I Disorders, Patient Edition<sup>31</sup> by centralized, expert interviewers conducting live, 2-way video patient interviews. Tobacco smoking status was obtained with the Fagerström questionnaire.<sup>32</sup>


Patients underwent research assessments of height (Seca 217 stadiometer), weight plus fat mass and percentage (Tanita TBF-310GS scale), waist circumference, and systolic and diastolic blood pressure as well as fasting phlebotomy for electrolytes, liver and renal function, and levels of hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>), insulin, and lipids. Fasting glucose level was assessed clinically and collected from the patients' records.

For definitions and thresholds<sup>33-41</sup> for body composition and cardiometabolic outcomes, see eAppendix 2 in the Supplement.

### Statistical Analysis

Except for HDL-C and HbA<sub>1c</sub>, all metabolic parameter analyses were restricted to the 286 patients (94.1%) with fasting blood test results. Extreme outlying data were capped at 4 SDs above the mean for fasting triglycerides, glucose, and insulin in 1 individual each. One patient with type 1 insulin-dependent diabetes was excluded from the analysis of glucose, insulin, and homeostasis model assessment-estimated insulin resistance. Beyond descriptive analyses of the entire sample, categorical and continuous cardiovascular variables were compared by sex, race, ethnicity, and antipsychotic-naïve vs antipsychotic-exposed status using  $\chi^2$  test and *t* test or Fisher exact test as appropriate. Racial subgroups were compared using post hoc pairwise *t* test. No further adjustments for multiple comparisons were made. Because of nonnormal

Figure 1. Flow Diagram of Study Participants



<sup>a</sup> Potential research participants contacted by research staff.

<sup>b</sup> Potential participants meeting brief (preconsent) checklist.

<sup>c</sup> Potential participants who signed informed consent and agreed to participate in the study if eligibility criteria were met.

<sup>d</sup> After signing informed consent, patients submitted to diagnostic eligibility interview, during which major inclusion and exclusion criteria were assessed.

<sup>e</sup> For patients meeting eligibility on the diagnostic interview, enrollment into treatment occurred at the end of the baseline 2 visit, during which the final eligibility criteria were assessed.

distribution of duration of illness and antipsychotic treatment, Spearman  $\rho$  was used to assess correlations between these variables and continuous cardiometabolic variables (providing more power than categorical outcomes). Exploratory linear regression analyses of continuous cardiometabolic variables were performed to evaluate the contribution of specific second-generation antipsychotics (excluding asenapine, clozapine, and lurasidone hydrochloride [each  $n < 10$ ]), first-generation antipsychotics (grouped together), antipsychotic polypharmacy, and no baseline antipsychotic treatment (en-

tering treatment groups as binary variables). For analyses of body composition and blood pressure, linear regression models were adjusted for sex, age, race, and ethnicity. Because patients taking quetiapine fumarate had significantly higher fat percentage, all metabolic outcome models were additionally adjusted for fat percentage. Analyses were conducted with JMP version 5 statistical software (SAS Institute Inc), with  $\alpha = .05$  (2-sided).

## Results

### Demographic, Illness, Treatment, and Smoking Characteristics

The RAISE-ETP sample consists of 404 patients; 394 (97.5%) had 1 or more baseline assessments of body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), blood pressure, or metabolic assessment, composing the study sample (Figure 1). The mean (SD) age of patients was 23.6 (5.0) years; 73.1% of patients were male; 81.5% were non-Hispanic; and 54.6% were white (Table 1). Diagnoses included schizophrenia (53.8%), schizoaffective disorder (20.1%), schizophreniform disorder (16.0%), and psychotic disorder not otherwise specified or brief psychotic disorder (10.2%).

At baseline, 56.9% were referred from outpatient settings and 78.4% had at least 1 psychiatric hospitalization; 86.3% had received antipsychotics, of which 92.4% were second-generation antipsychotics (Table 1). The mean (SD) total lifetime antipsychotic treatment was 47.3 (46.1) days (95% CI, 42.7-51.9). Other psychotropic medications consisted mainly of antidepressants (32.0%), anticholinergics (17.3%), mood stabilizers (12.2%), and benzodiazepines (11.2%).

Males were significantly younger than females at first psychotic symptom onset ( $P = .04$ ) and baseline ( $P < .001$ ) (Table 1). More females than males had schizoaffective disorder ( $P < .001$ ) and received antidepressants ( $P = .001$ ) and benzodiazepines ( $P = .009$ ). Racial groups did not differ significantly regarding sex ( $P = .09$ ), age ( $P = .59$ ), baseline antipsychotic treatment group ( $P = .32$ ), or antipsychotic treatment duration ( $P = .97$ ).

Among all patients, 50.8% smoked cigarettes; significantly more males than females smoked (55.9% vs 36.8%, respectively;  $P < .001$ ) (Table 2). No patient received nicotine replacement or medication treatment for smoking (Figure 2).

### Body Composition

The mean (SD) BMI was 26.6 (6.7); 48.3% of patients were obese (22.1%) or overweight (26.2%) (Table 2). Females compared with males had significantly higher fat mass (mean [SD], 25.3 [16.3] vs 16.6 [13.4] kg, respectively;  $P < .001$ ) and fat percentage (mean [SD], 32.5% [10.8%] vs 19.0% [9.5%], respectively;  $P < .001$ ). Black patients had significantly higher fat mass than white patients (mean [SD], 21.6 [17.6] vs 18.0 [12.9] kg, respectively;  $P = .03$ ) (Table 3).

### Arterial Hypertension

Among the patients, 39.9% had prehypertension and 10.0% had hypertension but only 3.6% received antihypertensive drugs

Table 1. Demographic, Illness, and Treatment Characteristics by Sex

Characteristic	Total (N = 394)	Males (n = 288)	Females (n = 106)	P Value
Age, mean (SD), y	23.6 (5.0)	23.1 (4.4)	25.0 (6.3)	<.001
Age at first psychiatric illness, mean (SD), y	16.9 (6.5)	16.7 (6.2)	17.5 (7.0)	.28
Duration since onset of any first psychiatric illness, mean (SD), y	6.7 (6.7)	6.4 (6.3)	7.6 (7.9)	.13
Duration of untreated psychosis, median (IQR), wk	84.6 (25.9-270.9)	76.7 (24.9-280.9)	105.1 (31.6-260.0)	.31
Age at first psychotic symptoms, mean (SD), y	19.0 (6.2)	18.6 (5.5)	20.1 (7.9)	.04
Non-Hispanic ethnicity, No. (%)	321 (81.5)	229 (79.5)	92 (86.8)	.10
Race, No. (%)				
White	215 (54.6)	165 (57.3)	50 (47.2)	.09
Black	144 (36.6)	96 (33.3)	48 (45.3)	
Native American	22 (5.6)	19 (6.6)	3 (2.8)	
Asian	12 (3.1)	7 (2.4)	5 (4.7)	
Hawaiian	1 (0.3)	1 (0.4)	0	
Educational level, No. (%)				
Patient (n = 393)				
Postgraduate degree	1 (0.3)	0	1 (1.0)	.30
Some postgraduate education	9 (2.3)	7 (2.4)	2 (1.9)	
4 y of college	14 (3.6)	7 (2.4)	7 (6.7)	
Some secondary education	99 (25.2)	69 (24.0)	30 (28.6)	
High school diploma	128 (32.6)	97 (33.7)	31 (29.5)	
High school	125 (31.8)	95 (33.0)	30 (28.6)	
Eighth grade	12 (3.1)	9 (3.1)	3 (2.9)	
None	5 (1.3)	4 (1.4)	1 (1.0)	
Maternal (n = 327)				
Postgraduate degree	17 (5.2)	16 (6.7)	1 (1.1)	.04
Some postgraduate education	9 (2.8)	7 (2.9)	2 (2.3)	
4 y of college	62 (19.0)	44 (18.5)	18 (20.2)	
Some secondary education	75 (22.9)	61 (25.6)	14 (15.7)	
High school diploma	106 (32.4)	76 (31.9)	30 (33.7)	
High school	37 (11.3)	20 (8.4)	17 (19.1)	
Eighth grade	14 (4.3)	10 (4.2)	4 (4.5)	
None	7 (2.1)	4 (1.7)	3 (3.4)	
Primary SCID diagnosis, No. (%)				
Schizophrenia	212 (53.8)	161 (55.9)	51 (48.1)	.004
Schizoaffective disorder	79 (20.1)	45 (15.6)	34 (32.1)	
Schizophreniform disorder	63 (16.0)	50 (17.4)	13 (12.3)	
Psychotic disorder not otherwise specified	40 (10.2)	32 (11.1)	8 (7.6)	
Outpatient treatment setting at baseline, No. (%)	224 (56.9)	155 (53.8)	69 (65.1)	.20
Duration of antipsychotic treatment, mean (SD), d	47.3 (46.1)	46.6 (43.5)	49.3 (52.6)	.61

(continued)

(Table 2 and Figure 2). Males had significantly higher systolic ( $P < .001$ ) and diastolic ( $P = .01$ ) blood pressure and more frequent prehypertension ( $P < .001$ ) than females, who received more antihypertensives ( $P = .047$ ).

### Lipid Metabolism

Altogether, 56.5% had at least 1 abnormality in low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol (HDL-C), HDL-C, or triglycerides level but

only 0.5% received lipid-lowering medications (Table 2 and Figure 2). Males had lower HDL-C ( $P < .001$ ) and higher triglycerides ( $P = .03$ ) (Table 2). White patients compared with black patients had higher triglycerides ( $P < .001$ ), more hypertriglyceridemia ( $P = .002$ ) and dyslipidemia ( $P < .001$ ), and lower HDL-C ( $P < .001$ ) (Table 3). Hispanic patients had more dyslipidemia than non-Hispanic patients, driven by more elevated non-HDL-C (both  $P = .03$ ) (Table 3).

Table 1. Demographic, Illness, and Treatment Characteristics by Sex (continued)

Characteristic	Total (N = 394)	Males (n = 288)	Females (n = 106)	P Value
Antipsychotic treatment, No. (%)				
Risperidone	108 (27.4)	88 (30.6)	20 (18.9)	.17
None	54 (13.7)	33 (11.5)	21 (19.8)	
Olanzapine	49 (12.4)	40 (13.9)	9 (8.5)	
Antipsychotic polypharmacy	37 (9.4)	27 (9.4)	10 (9.4)	
Aripiprazole	35 (8.9)	21 (7.3)	14 (13.2)	
Paliperidone palmitate	34 (8.6)	23 (8.0)	11 (10.4)	
Quetiapine fumarate	28 (7.1)	20 (6.9)	8 (7.6)	
First-generation antipsychotic	26 (6.6)	18 (6.3)	8 (7.6)	
Ziprasidone hydrochloride	12 (3.1)	9 (3.1)	3 (2.8)	
Lurasidone hydrochloride	7 (1.9)	6 (2.1)	1 (0.9)	
Clozapine	2 (0.5)	2 (0.7)	0	
Asenapine	2 (0.5)	1 (0.4)	1 (0.9)	
Nonantipsychotic comedication, No. (%)				
Antidepressant	126 (32.0)	79 (27.4)	47 (44.3)	.001
Anticholinergic	68 (17.3)	53 (18.4)	15 (14.2)	.32
Antiepileptic, lithium carbonate, or lithium citrate	48 (12.2)	36 (12.5)	12 (11.3)	.75
Benzodiazepine	44 (11.2)	25 (8.7)	19 (18.1)	.009
Nonbenzodiazepine hypnotic	20 (5.1)	13 (4.5)	7 (6.6)	.40
Psychostimulant or atomoxetine hydrochloride	6 (1.5)	5 (1.7)	1 (1.0)	>.99

Abbreviations: IQR, interquartile range; SCID, Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition.

### Carbohydrate Metabolism

Based on fasting glucose level (available in 101 of 286 fasting patients [34.0%]), prediabetes and diabetes were present in 4.0% and 3.0% of patients, respectively (Table 2 and Figure 2). Prevalence figures for HbA<sub>1c</sub>-defined prediabetes and diabetes were 15.4% and 2.9%, respectively. Hyperinsulinemia occurred in 12.7% of patients and insulin resistance based on the triglycerides to HDL-C ratio was present in 21.7%. Males had significantly higher insulin resistance based on the triglycerides to HDL-C ratio than females ( $P = .01$ ), who had glucose-defined diabetes significantly more often (3 females and 0 males;  $P = .04$ ) (Table 2). Black patients had significantly higher HbA<sub>1c</sub>-defined prediabetes than white patients ( $P < .001$ ), who had significantly higher triglycerides to HDL-C ratios than black patients ( $P < .001$ ) (Table 3).

### Metabolic Syndrome

Among the patients, 13.2% had metabolic syndrome (Table 2). While males fulfilled elevated blood pressure criteria significantly more often than females ( $P = .02$ ; although more females received antihypertensive medication counting toward this criterion), abdominal obesity was more than 3 times as common in females (45.6% in females vs 14.7% in males;  $P < .001$ ). This finding was independent of the lower threshold for abdominal obesity in females than males (>88 vs >102 cm, respectively), as females had more abdominal obesity than males when using a threshold greater than 102 cm for both groups (25.2% vs 14.7%, respectively;  $P = .002$ ) (Table 2). Consistent with continuous variables, significantly more white patients fulfilled hypertriglyceridemia ( $P < .001$ ) and low HDL-C ( $P = .004$ ) criteria than black patients (Table 3).

### Illness Duration and Cardiometabolic Risk

Abnormalities in each body composition parameter and triglycerides to HDL-C ratio were associated with longer duration of psychiatric illness (mean [SD], 6.7 [6.7] years; median, 4.3 years) (Table 4). No other metabolic variables were significantly associated with illness duration.

### Antipsychotic Exposure and Cardiometabolic Risk

Duration of lifetime antipsychotic treatment was associated with lower systolic blood pressure ( $P = .003$ ) and greater abnormalities in measures of HDL-C ( $P = .02$ ), non-HDL-C ( $P = .01$ ), triglycerides ( $P = .01$ ), and triglycerides to HDL-C ratio ( $P = .005$ ) (Table 4). Although glucose level was inversely related to antipsychotic treatment duration ( $P = .02$ ), results were based on only 99 patients with data.

Compared with patients with any lifetime antipsychotic exposure, antipsychotic-naïve patients had lower non-HDL-C levels ( $P = .04$ ). However, more antipsychotic-naïve patients were obese ( $P = .01$ ) and had hypertension ( $P = .03$ ), and more patients in this group fulfilled the abdominal obesity ( $P = .003$ ) and elevated blood pressure ( $P = .03$ ) criteria for metabolic syndrome, which was also more frequent than in the antipsychotic-exposed patients ( $P = .04$ ) (eTable 1 in the Supplement).

Comparing baseline treatment groups, not using antipsychotics at the time of blood draw was associated with significantly lower levels of total cholesterol and low-density lipoprotein cholesterol (both  $P = .03$ ). Moreover, higher levels of triglycerides ( $P = .007$ ), insulin ( $P = .02$ ), and homeostasis model assessment-estimated insulin resistance ( $P < .001$ ) were associated with olanzapine therapy, while a higher triglycerides to HDL-C ratio was associated with quetiapine ( $P = .02$ ) (eTable 2 in the Supplement).



**Table 2. Cardiometabolic Risk Status and Treatment at Baseline by Sex**

Variable	Total (N = 394)	Males (n = 288)	Females (n = 106)	P Value	NHANES	
					Age 20-29 y	Age Mid-40s
Smoking, No. (%) (n = 394)	200 (50.8)	161 (55.9)	39 (36.8)	<.001	36.7% for males, 24.9% for females <sup>42</sup>	
Body composition						
BMI, mean (SD) (n = 389)	26.6 (6.7)	26.3 (6.0)	27.3 (8.3)	.17		
Weight status, No. (%) (n = 389)						
Underweight	8 (2.1)	3 (1.1)	5 (4.8)	.02	25% (ages 20-24 y) <sup>43</sup>	
Normal	193 (49.6)	144 (50.7)	49 (46.7)			
Overweight	102 (26.2)	81 (28.5)	21 (20.0)			
Obese	86 (22.1)	56 (19.7)	30 (28.6)			
Fat mass, mean (SD), kg (n = 373)	19.0 (14.3)	16.6 (13.4)	25.3 (16.3)	<.001		
Fat %, mean (SD) (n = 375)	22.7 (9.8)	19.0 (9.5)	32.5 (10.8)	<.001		
Waist circumference, mean (SD), cm (n = 388)	91.1 (16.3)	91.1 (15.6)	91.2 (18.3)	.95		
Abdominal obesity, waist circumference >102 cm for males and females, No. (%) (n = 388)	68 (17.5)	42 (14.7)	26 (25.2)	.002		
Arterial blood pressure (n = 389)						
Mean (SD), mm Hg						
Systolic	117.1 (12.4)	120.1 (12.2)	108.6 (13.0)	<.001		
Diastolic	75.5 (9.9)	76.3 (9.6)	73.4 (10.7)	.01		
Prehypertension, blood pressure 120-139/80-89 mm Hg, No. (%)	155 (39.9)	134 (47.0)	21 (20.2)	<.001	20.9% <sup>44</sup>	
Hypertension, blood pressure ≥140/90 mm Hg, No. (%)	39 (10.0)	31 (10.9)	8 (7.7)	.35	49.9% <sup>44</sup>	
Fasting lipid metabolism (n = 286) <sup>a</sup>						
Total cholesterol, mean (SD), mg/dL	173.4 (35.5)	173.4 (37.2)	173.3 (30.5)	.97		
Hypercholesterolemia, total cholesterol ≥200 mg/dL, No. (%)	61 (21.0)	46 (21.7)	15 (19.2)	.65		
LDL-C, mean (SD), mg/dL	100.7 (31.1)	101.4 (32.6)	99.9 (26.6)	.56		
Elevated LDL-C, ≥130 mg/dL, No. (%)	49 (17.1)	38 (18.3)	11 (14.1)	.40	27% <sup>35</sup>	
Fasting and nonfasting HDL-C, mean (SD), mg/dL (n = 304)	49.2 (12.8)	47.4 (12.0)	54.2 (14.6)	<.001		
Non-HDL-C, mean (SD), mg/dL	124.0 (35.8)	125.8 (37.8)	119.1 (29.9)	.16		
Elevated non-HDL-C, ≥130 mg/dL, mean (SD)	116 (40.6)	89 (42.8)	27 (34.6)	.21		
Triglycerides, mean (SD), mg/dL	115.4 (77.5)	121.7 (84.9)	98.8 (52.9)	.03		
Hypertriglyceridemia, triglycerides ≥170 mg/dL, No. (%)	46 (16.1)	37 (17.8)	9 (11.5)	.20	30% <sup>35</sup>	
Dyslipidemia, No. (%) <sup>b</sup>	161 (56.5)	115 (55.6)	46 (59.0)	.60	53% <sup>35</sup>	
Fasting carbohydrate metabolism <sup>a</sup>						
HbA <sub>1c</sub> , mean (SD), % (n = 280)	5.4 (0.7)	5.3 (0.4)	5.5 (1.1)	.05		
Glucose, mean (SD), mg/dL (n = 100) <sup>c</sup>	86.4 (17.9)	85.2 (13.4)	88.6 (24.5)	.37		
Insulin, mean (SD), μIU/mL (n = 235) <sup>c</sup>	11.6 (13.6)	11.8 (14.6)	11.1 (10.8)	.71		
Hyperinsulinemia, insulin >20 μIU/mL, No. (%) (n = 235)	30 (12.7)	22 (12.9)	8 (12.3)	.91		
HOMA-IR, mean (SD) (n = 235) <sup>c</sup>	3.1 (3.8)	3.0 (3.4)	3.2 (4.4)	.84		
Triglycerides to HDL-C ratio (n = 286)						
Mean (SD)	2.6 (2.2)	2.9 (2.4)	2.1 (1.6)	.01		
Ratio ≥3.5, No. (%)	62 (21.7)	51 (24.5)	11 (14.1)	.06		
Prediabetes, No. (%)						
Glucose based, 100-125 mg/dL (n = 101)	4 (4.0)	3 (4.6)	1 (2.9)	>.99		
HbA <sub>1c</sub> based, 5.7%-6.4% (n = 280)	43 (15.4)	27 (13.4)	16 (20.5)	.14		
Diabetes, No. (%)						
Glucose based, >125 mg/dL (n = 101)	3 (3.0)	0	3 (8.6)	.04		
HbA <sub>1c</sub> based, >6.4% (n = 280)	8 (2.9)	5 (2.5)	3 (3.9)	.69		

(continued)

Table 2. Cardiometabolic Risk Status and Treatment at Baseline by Sex (continued)

Variable	Total (N = 394)	Males (n = 288)	Females (n = 106)	P Value	NHANES	
					Age 20-29 y	Age Mid-40s
Metabolic syndrome and individual criteria, No. (%)						
Metabolic syndrome, fasting glucose $\geq 100$ mg/dL per ATP III (n = 257)	34 (13.2)	21 (11.2)	13 (18.6)	.12	6.7% <sup>41, d</sup>	21.8% <sup>41, d</sup>
Low HDL-C, <40 mg/dL in males and <50 mg/dL in females (n = 305)	91 (29.8)	61 (27.4)	30 (35.6)	.12		37.1% <sup>41</sup>
Abdominal obesity, waist circumference >102 cm in males and >88 cm in females (n = 388)	89 (22.9)	42 (14.7)	47 (45.6)	<.001		38.6% <sup>41</sup>
Elevated blood pressure, $\geq 130/80$ mm Hg, or antihypertensive treatment (n = 389)	92 (23.7)	76 (26.7)	16 (15.4)	.02		34.0% <sup>41</sup>
Elevated triglycerides, $\geq 150$ mg/dL (n = 286)	62 (21.7)	50 (24.0)	12 (15.4)	.11		30.0% <sup>41</sup>
Hyperglycemia, glucose $\geq 100$ mg/dL (n = 101)	7 (7.0)	3 (4.6)	4 (11.4)	.69		12.6% <sup>41, d</sup>
Cardiometabolic treatment medication, No. (%)						
Antihypertensive	14 (3.6)	7 (2.4)	7 (6.6)	.047		
Antidiabetic	3 (0.8)	1 (0.4)	2 (1.9)	.18		
Lipid lowering	2 (0.5)	2 (0.7)	0	>.99		

Abbreviations: ATP III, Adult Treatment Panel III; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub>; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-estimated insulin resistance; LDL-C, low-density lipoprotein cholesterol; NHANES, National Health and Nutrition Examination Survey.

SI conversion factors: To convert fat mass to pounds, divide by 0.45; to convert total cholesterol, LDL-C, HDL-C, and non-HDL-C to millimoles per liter, multiply by 0.0259; to convert triglycerides to millimoles per liter, multiply by 0.0113; to convert HbA<sub>1c</sub> from percentage of total hemoglobin to proportion of total hemoglobin, multiply by 0.01; to convert glucose to millimoles per liter, multiply by 0.0555; and to convert insulin to picomoles per liter, multiply by 6.945.


<sup>a</sup> Because HDL-C and HbA<sub>1c</sub> are not affected by time from last food ingestion, their data include nonfasting patients.

<sup>b</sup> Defined as an elevated LDL-C level ( $\geq 130$  mg/dL), non-HDL-C level ( $\geq 130$  mg/dL), or triglycerides level ( $\geq 150$  mg/dL) or a low HDL-C level (<40 mg/dL in males and <50 mg/dL in females).

<sup>c</sup> One patient with type 1 insulin-dependent diabetes was excluded from the analysis of glucose, insulin, and HOMA-IR levels.

<sup>d</sup> The NHANES definition of metabolic syndrome uses a fasting glucose level of 110 mg/dL or higher as the glucose abnormality criterion instead of the currently used metabolic syndrome definition with a fasting glucose threshold of 100 mg/dL or higher.

Figure 2. Prevalence of Smoking, Lipid Abnormalities, Hypertension, Diabetes, and Metabolic Syndrome and Respective Medication Treatment for the Conditions



Dyslipidemia indicates an elevated low-density lipoprotein cholesterol (LDL-C) level ( $\geq 130$  mg/dL; to convert to millimoles per liter, multiply by 0.0259), an elevated non-high-density lipoprotein cholesterol (HDL-C) level ( $\geq 130$  mg/dL; to convert to millimoles per liter, multiply by 0.0259), an elevated triglycerides level ( $\geq 150$  mg/dL; to convert to millimoles per liter, multiply by 0.0113), or a low HDL-C level (<40 mg/dL in males and <50 mg/dL in females; to convert to millimoles per liter, multiply by 0.0259). HbA<sub>1c</sub> indicates hemoglobin A<sub>1c</sub>.

## Discussion

Despite the young age of this study sample of 394 patients with FES, an average of only 47 days of lifetime antipsychotic ex-

posure, and overweight and obesity figures comparable to those for similarly aged US population members,<sup>43</sup> there was a clear pattern of increased smoking<sup>42</sup> and several metabolic risk indices<sup>41,44</sup> compared with similarly aged persons in the general US population. Moreover, dyslipidemia was as frequent

**Table 3. Cardiometabolic Risk Status and Treatment at Baseline by Race and Ethnicity**

Variable	Race				P Value	Ethnicity		
	White (n = 215)	Black (n = 144)	Native American (n = 22)	Asian (n = 12)		Non-Hispanic (n = 321)	Hispanic (n = 73)	P Value
Smoking, No. (%) (n = 393)	117 (54.4)	70 (48.6)	9 (40.9)	4 (33.3)	.29	172 (53.6)	28 (38.4)	.02
Body composition								
BMI, mean (SD) (n = 389)	26.2 (6.2)	27.5 (7.4)	26.2 (6.7)	23.0 (3.6)	.08	26.7 (6.8)	26.1 (6.2)	.52
Weight status, No. (%) (n = 389)								
Underweight	5 (2.4)	1 (0.7)	1 (4.6)	1 (8.3)	.25	8 (2.5)	0	.20
Normal	102 (47.9)	71 (50.4)	12 (54.6)	7 (58.3)		151 (47.9)	42 (59.2)	
Overweight	61 (28.6)	31 (22.0)	6 (27.3)	4 (33.3)		85 (26.7)	17 (23.9)	
Obese	45 (21.1)	38 (27.0)	3 (13.6)	0		74 (23.3)	12 (16.9)	
Fat mass, mean (SD), kg (n = 373)	18.0 (12.9)	21.6 (17.6)	16.3 (13.6)	12.4 (5.8)	.04 <sup>a</sup>	19.5 (15.6)	16.6 (9.9)	.14
Fat %, mean (SD) (n = 375)	21.8 (10.9)	24.6 (12.7)	20.6 (9.9)	18.9 (6.9)	.07	22.8 (11.8)	22.1 (10.2)	.68
Waist circumference, mean (SD), cm (n = 387)	91.3 (14.3)	92.2 (19.0)	89.3 (17.8)	79.1 (8.3)	.06	91.5 (16.8)	89.3 (13.7)	.28
Arterial blood pressure (n = 388)								
Mean (SD), mm Hg								
Systolic	116.4 (12.7)	118.6 (14.2)	115.5 (14.9)	115.4 (14.2)	.43	117.6 (13.2)	114.6 (14.1)	.09
Diastolic	74.9 (9.5)	77.1 (10.6)	72.3 (9.6)	72.6 (8.1)	.06	75.9 (9.5)	73.8 (11.5)	.11
Prehypertension, blood pressure 120-139/80-89 mm Hg, No. (%)	90 (42.3)	50 (35.2)	10 (47.6)	5 (41.7)	.51	128 (40.4)	27 (37.5)	.65
Hypertension, blood pressure ≥140/90 mm Hg, No. (%)	19 (8.9)	20 (14.1)	0	0	.09	31 (9.8)	8 (11.1)	.73
Fasting lipid metabolism (n = 286) <sup>b</sup>								
Total cholesterol, mean (SD), mg/dL	175.3 (35.7)	171.3 (35.8)	171.7 (36.6)	172.6 (25.6)	.84	172.7 (34.8)	175.8 (37.7)	.55
Hypercholesterolemia, total cholesterol ≥200 mg/dL, No. (%)	36 (23.2)	19 (17.8)	5 (27.8)	1 (11.1)	.54	46 (20.4)	15 (23.4)	.59
LDL-C, mean (SD), mg/dL	102.8 (30.3)	99.3 (34.0)	97.2 (26.2)	93.0 (12.9)	.65	100.2 (31.2)	102.7 (31.0)	.58
Elevated LDL-C, ≥130 mg/dL, No. (%)	30 (19.9)	15 (14.0)	4 (23.5)	0	.28	38 (17.1)	11 (17.5)	.95
Fasting and nonfasting HDL-C, mean (SD), mg/dL (n = 303)	46.3 (11.8)	53.0 (13.7)	50.2 (15.7)	53.1 (10.4)	<.001 <sup>c</sup>	49.7 (12.9)	47.5 (13.9)	.24
Non-HDL-C, mean (SD), mg/dL	128.9 (36.2)	118.3 (36.1)	120.6 (33.1)	119.4 (23.3)	.12	122.9 (35.9)	127.8 (35.8)	.34
Elevated non-HDL-C, ≥130 mg/dL, mean (SD)	72 (47.4)	35 (32.7)	5 (29.4)	4 (44.4)	.09	83 (37.2)	33 (52.4)	.03
Triglycerides, mean (SD), mg/dL	133.2 (89.1)	90.1 (55.5)	111.7 (59.9)	126.7 (66.3)	<.001 <sup>d</sup>	112.0 (72.3)	122.7 (67.8)	.29
Hypertriglyceridemia, triglycerides ≥170 mg/dL, No. (%)	35 (22.9)	9 (8.4)	1 (5.9)	2 (22.2)	.01	37 (16.5)	10 (15.9)	.90
Dyslipidemia, No. (%) <sup>e</sup>	100 (66.2)	48 (44.9)	8 (47.1)	5 (55.6)	.006	118 (53.2)	43 (68.3)	.03
Fasting carbohydrate metabolism <sup>b</sup>								
HbA <sub>1c</sub> , mean (SD), % (n = 279)	5.3 (0.8)	5.5 (0.4)	5.4 (0.5)	5.3 (0.2)	.26	5.4 (0.7)	5.3 (0.3)	.83
Glucose, mean (SD), mg/dL (n = 100) <sup>f</sup>	87.4 (14.9)	85.4 (13.7)	83.6 (14.2)	68.7 (8.6)	.17	86.0 (14.9)	83.9 (11.4)	.60
Insulin, mean (SD), μIU/mL (n = 234) <sup>f</sup>	10.8 (11.5)	12.8 (15.0)	18.1 (28.7)	8.4 (5.4)	.23	11.9 (13.5)	12.1 (18.0)	.94
Hyperinsulinemia, insulin >20 μIU/mL, No. (%) (n = 234)	13 (10.9)	14 (15.4)	3 (18.8)	0	.46	25 (13.4)	5 (10.2)	.64
HOMA-IR, mean (SD) (n = 234) <sup>f</sup>	3.7 (5.8)	3.1 (4.4)	4.8 (5.6)	0.9 (0.6)	.70	3.4 (5.2)	3.5 (4.6)	.93
Triglycerides to HDL-C ratio (n = 285)								
Mean (SD)	3.1 (2.3)	2.0 (1.8)	2.4 (1.6)	2.5 (1.6)	<.001 <sup>d</sup>	2.6 (2.1)	2.9 (1.9)	.32
Ratio ≥3.5, No. (%)	46 (30.3)	11 (10.3)	2 (11.8)	3 (33.3)	<.001	47 (21.1)	15 (23.8)	.64
Prediabetes, No. (%)								
Glucose based, 100-125 mg/dL (n = 101)	3 (7.1)	1 (2.2)	0	0	.60	3 (3.7)	1 (5.9)	.54
HbA <sub>1c</sub> based, 5.7%-6.4% (n = 280)	12 (8.1)	31 (29.3)	1 (5.6)	0	<.001	36 (16.3)	8 (13.3)	.58
Diabetes, No. (%)								
Glucose based, >125 mg/dL (n = 101)	2 (4.6)	1 (2.2)	0	0	.85	3 (3.6)	0	>.99
HbA <sub>1c</sub> based, >6.4% (n = 280)	3 (2.0)	5 (4.7)	1 (5.6)	0	.57	8 (3.6)	1 (1.7)	.54

(continued)



Table 3. Cardiometabolic Risk Status and Treatment at Baseline by Race and Ethnicity (continued)

Variable	Race				P Value	Ethnicity		P Value
	White (n = 215)	Black (n = 144)	Native American (n = 22)	Asian (n = 12)		Non-Hispanic (n = 321)	Hispanic (n = 73)	
Metabolic syndrome and individual criteria, No. (%)								
Metabolic syndrome, fasting glucose $\geq 100$ mg/dL per ATP III (n = 258)	24 (17.9)	8 (8.1)	2 (13.3)	0	.11	30 (14.5)	4 (8.0)	.22
Low HDL-C, $<40$ mg/dL in males and $<50$ mg/dL in females (n = 304)	61 (37.4)	25 (21.9)	5 (27.8)	0	.008	69 (28.8)	22 (33.9)	.43
Abdominal obesity, waist circumference $>102$ cm in males and $>88$ cm in females (n = 387)	49 (22.9)	37 (26.6)	3 (13.6)	0	.13	77 (24.3)	12 (16.7)	.16
Elevated blood pressure, $\geq 130/80$ mm Hg, or antihypertensive treatment (n = 388)	45 (21.1)	41 (28.9)	5 (23.8)	1 (8.3)	.22	77 (24.3)	15 (20.8)	.53
Elevated triglycerides, $\geq 150$ mg/dL (n = 285)	47 (30.7)	11 (10.3)	2 (11.8)	3 (33.3)	$<.001$	50 (22.3)	13 (20.6)	.78
Hyperglycemia, glucose $\geq 100$ mg/dL (n = 101)	5 (11.4)	2 (4.4)	0	0	.45	6 (7.1)	1 (5.9)	$>.99$
Cardiometabolic treatment medication, No. (%)								
Antihypertensive	6 (2.8)	8 (5.6)	0	0	.35	13 (4.1)	1 (1.4)	.48
Antidiabetic	1 (0.5)	2 (1.4)	0	0	.74	3 (0.9)	0	$>.99$
Lipid lowering	1 (0.5)	1 (0.7)	0	0	.96	2 (0.6)	0	$>.99$

Abbreviations: ATP III, Adult Treatment Panel III; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub>; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment–estimated insulin resistance; LDL-C, low-density lipoprotein cholesterol.

SI conversion factors: To convert fat mass to pounds, divide by 0.45; to convert total cholesterol, LDL-C, HDL-C, and non-HDL-C to millimoles per liter, multiply by 0.0259; to convert triglycerides to millimoles per liter, multiply by 0.0113; to convert HbA<sub>1c</sub> from percentage of total hemoglobin to proportion of total hemoglobin, multiply by 0.01; to convert glucose to millimoles per liter, multiply by 0.0555; and to convert insulin to picomoles per liter, multiply by 6.945.

<sup>a</sup> Greater for black patients than for white and Asian patients ( $P < .05$ , post hoc pairwise *t* test).

<sup>b</sup> Because HDL-C and HbA<sub>1c</sub> are not affected by time from last food ingestion, their data include nonfasting patients.

<sup>c</sup> Lower for white patients than for black patients ( $P < .05$ , post hoc pairwise *t* test).

<sup>d</sup> Greater for white patients than for black patients ( $P < .05$ , post hoc pairwise *t* test).

<sup>e</sup> Defined as an elevated LDL-C level ( $\geq 130$  mg/dL), non-HDL-C level ( $\geq 130$  mg/dL), or triglycerides level ( $\geq 150$  mg/dL) or a low HDL-C level ( $<40$  mg/dL in males and  $<50$  mg/dL in females).

<sup>f</sup> One patient with type 1 insulin-dependent diabetes was excluded from the analysis of glucose, insulin, and HOMA-IR levels.

as in adults 15 to 20 years older in the general US population.<sup>35</sup> Further, body composition-related risk markers were significantly associated with longer total psychiatric illness duration, whereas metabolic risk markers were significantly associated with the overall very short mean lifetime antipsychotic treatment duration. Finally, relevant for treatment choice and recommendations for patients with FES, significantly higher continuous metabolic risk factor values were associated with olanzapine and less so with quetiapine.

Altogether, about half the patients with FES smoked tobacco or had dyslipidemia, 39.9% had prehypertension, 10.0% were hypertensive, and a substantial minority (13.2%) had metabolic syndrome. Furthermore, while 3.0% were already diabetic, as many as 15.4% had HbA<sub>1c</sub>-defined prediabetes, which has an 8-year risk for diabetes comparable to fasting glucose-defined prediabetes.<sup>45</sup> Smoking was dramatically more frequent in our study's patients than in young US adults in 2009 to 2011<sup>42</sup> (males: 55.9% vs 36.7%, respectively; females: 36.8% vs 24.9%, respectively). Further, compared with 20- to 29-year-olds in the general US population,<sup>43</sup> metabolic syndrome was more prevalent in patients with FES (7.0% vs 13.2%,

respectively; +89%), although obesity was similarly common as in US adults aged 20 to 24 years.<sup>43</sup> Because that National Health and Nutrition Examination Survey metabolic syndrome definition used a fasting glucose level of 110 mg/dL or higher (to convert to millimoles per liter, multiply by 0.0555)<sup>44</sup> instead of the now-used threshold of 100 mg/dL or higher<sup>40</sup> as the glucose abnormality criterion, some of the observed difference may be influenced by this methodological difference. Additionally, the 56.5% dyslipidemia prevalence in patients with FES was at least as high as the 53% figure reported for US adults averaging 20 years older.<sup>35</sup> Prehypertension (systolic/diastolic blood pressure of 120-139/80-89 mm Hg) was present in 39.9%, which was much more frequent than in 17 794 participants in the 1999 to 2006 National Health and Nutrition Examination Survey (20.9%), whose average age was 20 years older,<sup>44</sup> even if some of this difference may have been due to the higher hypertension frequency in the older general population sample. Although values in this first-episode US sample were generally somewhat higher than those reported in 3 European first-episode samples,<sup>46-48</sup> the findings converge in that the body weight and metabolic indices were

**Table 4. Correlations Between Mean Continuous Cardiometabolic Health Parameters and Lifetime Durations of Psychiatric Illness and Antipsychotic Treatment**

Variable	Total Psychiatric Illness Duration			Cumulative Antipsychotic Treatment Duration		
	No.	Spearman $\rho^a$	P Value	No.	Spearman $\rho^a$	P Value
<b>Body composition</b>						
BMI	383	0.149	.003	388	0.047	.36
Fat mass	368	0.157	.002	373	0.044	.40
Fat %	370	0.156	.003	373	0.004	.93
Waist circumference	383	0.138	.007	388	-0.011	.98
<b>Blood pressure</b>						
Systolic	384	0.008	.88	389	-0.152	.003
Diastolic	384	0.053	.30	389	-0.057	.27
<b>Fasting blood lipids<sup>b</sup></b>						
Total cholesterol	283	0.097	.10	286	0.099	.10
LDL-C	282	0.076	.21	285	0.089	.14
HDL-C	301	-0.065	.26	304	-0.129	.02
Non-HDL-C	283	0.107	.07	286	0.151	.01
Triglycerides	283	0.115	.05	286	0.149	.01
Triglycerides to HDL-C ratio	281	0.125	.04	286	0.167	.005
<b>Fasting carbohydrate metabolism<sup>b</sup></b>						
HbA <sub>1c</sub>	277	-0.061	.31	278	-0.064	.29
Glucose	99	0.162	.11	100	-0.230	.02
Insulin	234	0.030	.64	235	-0.021	.76
HOMA-IR	89	0.158	.14	90	-0.159	.13

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub>; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-estimated insulin resistance; LDL-C, low-density lipoprotein cholesterol.

<sup>a</sup> Positive Spearman  $\rho$  indicates a direct relationship; negative Spearman  $\rho$ , an

inverse relationship.

<sup>b</sup> Because HDL-C and HbA<sub>1c</sub> are not affected by time from last food ingestion, their data include nonfasting patients.

similar to those of the respective general population norms prior to treatment and that cardiometabolic abnormalities started to emerge early during antipsychotic exposure.

In our sample, body composition parameters, but not metabolic parameters (except for the triglycerides to HDL-C ratio), were significantly associated with longer psychiatric illness duration, indicating potential adverse changes in diet, exercise, and/or socioeconomic status related to psychiatric conditions such as depression and emerging psychosis. However, despite very short antipsychotic exposure, there was a significant effect of antipsychotic treatment duration on disturbed lipid metabolism and lipid-based proxy measures of early insulin resistance,<sup>37</sup> but not on body composition or carbohydrate metabolism indices. The latter may take longer to be significantly dysregulated by antipsychotics, especially in young patients, with the possible exception of olanzapine and clozapine.<sup>19-21,23</sup> Furthermore, longer antipsychotic treatment was associated with lower systolic blood pressure, consistent with the  $\alpha$ -adrenergic blockade of many antipsychotics.<sup>49</sup>

The relative contributions of schizophrenia, unhealthy lifestyle, psychotropic treatment, and insufficient medical care to elevated cardiovascular risk and mortality have been debated.<sup>1-13,15-17,20-25</sup> Comparing antipsychotic-naive patients with nonnaive patients yielded only a few differences, including higher frequencies of obesity, hypertension, and meta-

bolic syndrome (driven by more patients meeting abdominal obesity and elevated blood pressure criteria) but less elevated non-HDL-C (a major risk factor for cardiovascular illness) in the antipsychotic-naive group than in patients with lifetime antipsychotic exposure. These preliminary data are partially driven by the hypotensive effect of antipsychotics and the unexpectedly higher obesity rate in the antipsychotic-naive group. Our results are limited by the relatively small antipsychotic-naive sample and varying degrees of exposure in the nonnaive group. Taken together, these data support the view that cardiometabolic burden is partly due to psychiatric or psychotic illness and unhealthy lifestyle but accelerates after antipsychotics are initiated and taken for longer periods.<sup>20-24</sup>

The finding that higher levels of triglycerides, insulin, and insulin resistance were associated with olanzapine treatment is consistent with a large body of evidence regarding the cardiometabolic risk of olanzapine.<sup>20,21,24,50-53</sup> That this effect was observable this early is alarming and supports the Schizophrenia Patient Outcomes Research Team's recommendation that clozapine and olanzapine should not be given as first-line treatment in FES.<sup>54</sup> The finding that a higher triglycerides to HDL-C ratio, a marker of insulin resistance, was associated with quetiapine treatment is concerning. Together with other data suggesting a marked and early adverse lipid signal with quetiapine despite similar weight

gain as risperidone,<sup>19-21,23,50</sup> its first-line use in first-episode psychosis may need to be reevaluated.

With few exceptions, compared with meta-analytically pooled patients with FES enrolled in previous studies,<sup>55</sup> this real-world community sample had similar cardiometabolic risk frequencies. Notable exceptions in our sample compared with the other studies include higher rates of fasting glucose-defined diabetes (2.9% vs 1.3%, respectively; +120%) and low HDL-C (29.8% vs 21.9%, respectively; +36%). The frequency of smoking in this FES sample (50.8%) was also similar to that of prior FES samples<sup>55</sup> but only modestly lower than in the most recent population-based studies of patients of any age with schizophrenia (59.1%).<sup>56</sup> Of concern regarding future diabetes risk, the HbA<sub>1c</sub>-based prediabetes frequency (15.4%) was already 70% of that observed in patients with chronic schizophrenia (21.6%) who were 16 years older.<sup>57</sup>

Importantly, the relatively high prevalences of hypertension, diabetes, and especially smoking and lipid abnormalities are in stark contrast to the lack of related medical treatment in most patients. The underrecognition and undertreatment of cardiometabolic risk factors, especially lipid abnormalities, are consistent with previous reports among patients with chronic schizophrenia<sup>12,14-16</sup> and antipsychotic-treated patients<sup>58-60</sup> and are likely modifiable reasons for premature mortality in schizophrenia.<sup>1-11</sup> Furthermore, smoking causes diseases that disproportionately affect people with schizophrenia, including cardiovascular disease, diabetes, cancers, and pulmonary diseases, and may be a much stronger driver of cardiovascular morbidity and mortality than obesity.<sup>61-65</sup> Smoking cessation improves health outcomes at any age, but quitting early provides the most benefit.<sup>66</sup> Together with the fact that no patients with FES received nicotine replacement or medical interventions for smoking, these findings suggest that early education, engagement, and smoking cessation treatments are needed for patients with FES.<sup>66</sup>

We observed several significant sex differences. Consistent with the general population,<sup>67</sup> females had greater fat mass, higher fat percentage, more abdominal obesity, and more glucose-based diabetes. Despite this, also as in the general population, males had higher smoking rates, systolic and diastolic blood pressure, prehypertension rates, triglycerides levels, and triglycerides to HDL-C ratios and lower HDL-C levels. Notably, we confirmed higher abdominal obesity rates in females even when using the same waist circumference threshold as in males. Abdominal obesity was similarly more prevalent in females in the chronic schizophrenia population of the Clinical Antipsychotic Trials of Intervention Effectiveness study.<sup>68</sup> As in our sample, sex differences in metabolic syndrome were also not present among young people in the National Health and Nutrition Examination Survey general population survey but emerged among older people,<sup>67</sup> particularly among black and Hispanic patients.

Given that adiposity is a stronger predictor of cardiovascular risk than BMI (which was similar between males and females in our sample), females with FES may be a particularly high-risk cardiometabolic group. Nevertheless, arterial hypertension and an increased triglycerides to HDL-C ratio, an early

indicator of insulin resistance,<sup>37</sup> which were more prevalent in males, are also cardiovascular risk factors. Thus, prospective studies are needed to assess how these different risk factors affect cardiovascular morbidity and mortality over time, especially because antipsychotic treatment and potential changes in healthy behaviors and socioeconomic status due to chronic psychiatric illness further increase the risk.

No significant differences emerged between Hispanic and non-Hispanic patients except that, consistent with general population data,<sup>69,70</sup> more non-Hispanic than Hispanic patients with FES smoked, while Hispanic patients with FES more often had an elevated non-HDL-C level and dyslipidemia. However, several relevant racial differences emerged. Consistent with the general population,<sup>71-74</sup> despite greater fat mass, black patients had significantly lower triglycerides levels and triglycerides to HDL-C ratios than white patients. Contrary to the triglycerides level and also similar to the general population,<sup>75-77</sup> black patients had HbA<sub>1c</sub>-defined prediabetes significantly more often than white patients. A greater frequency of HbA<sub>1c</sub>-defined prediabetes, which is a sign of impaired postprandial glycemic control, is alarming as retinopathy starts at even lower HbA<sub>1c</sub> levels in black individuals than in white individuals.<sup>78</sup>

Taken together, our findings highlight major opportunities for improvement in health care planning and delivery for people with schizophrenia. Our data underscore that warnings by the US Food and Drug Administration regarding diabetes risk of antipsychotics plus need for health monitoring and subsequent national and international guidelines<sup>18</sup> have been insufficient to positively affect the health disparity for patients with schizophrenia even at the beginning of their treatment.<sup>12,14</sup> Instead, there is a need for policy changes that promote the implementation of integrated care, health homes, and accountable care organizations wherein coordinated attention to both physical and mental health care needs will lead to improved health and reduced expenditure.<sup>6</sup>

Several limitations warrant attention. First, only 50 participants were antipsychotic naive, making comparisons with previously exposed patients preliminary. Second, the naturalistic nature of antipsychotic treatment and multiple analyses without adjustment for multiple testing limit our ability to assign causality to differences in cardiometabolic risk between medication groups. In fact, differences in medications' adverse effects may have been masked by clinicians' selective treatment of higher-risk (overweight or obese) patients with lower-risk antipsychotics, eg, aripiprazole and ziprasidone hydrochloride. Moreover, glucose level was not part of the initial research assessments and was therefore available for only a subgroup. Furthermore, fat mass, fat percentage, and insulin resistance were assessed with generalizable clinical measures and not gold-standard techniques, and we did not assess exercise or diet. Additionally, racial groups other than white or black patients were small, as were some of the individual antipsychotic treatment groups. Finally, data on the exact history of type and sequence of antipsychotic treatment prior to the baseline antipsychotic were not complete enough to allow such analyses. Nevertheless, this is a large study of patients with FES who had limited lifetime antipsychotic ex-

posure and were recruited from 34 community treatment sites in 21 states, which yielded results on cardiometabolic health that are reflective of general clinical practice settings in the United States. The limited number of eligible patients refusing participation increases generalizability of the findings. That 78.4% of RAISE-ETP patients had at least 1 hospitalization is likely due to the well-known problem that patients remained untreated in the community and only received psychiatric attention when symptoms became severe enough to warrant hospitalization, and although unfortunate, this rate generalizes to a broader US population. Furthermore, despite naturalistic treatment, individual antipsychotic groups did not significantly differ in duration of prior antipsychotic treatment, BMI, fat mass, or waist circumference, reducing the potential bias on laboratory measures and blood pressure.

## Conclusions

Early in psychotic illness and after a mean of only 6.7 weeks of antipsychotic exposure, lipid abnormalities and insulin resistance markers were elevated and significantly related to lifetime and individual antipsychotic exposure. These results reinforce the importance of assessing all patients for cardiometabolic risk prior to and throughout treatment, choosing low-risk antipsychotics, and managing cardiometabolic adverse effects that emerge in the care of patients with FES.<sup>12,20,21,79</sup> Further research is needed to assess the trajectory of cardiometabolic risk, underlying mechanisms, and mediating variables, including preferred treatment choices for FES and/or cardiometabolic risk factors.

### ARTICLE INFORMATION

**Submitted for Publication:** October 29, 2013; final revision received June 1, 2014; accepted June 9, 2014.

**Published Online:** October 8, 2014.  
doi:10.1001/jamapsychiatry.2014.1314.

**Author Affiliations:** Division of Psychiatry Research, North Shore-LIJ Health System, The Zucker Hillside Hospital, Glen Oaks, New York (Correll, D. G. Robinson, Schooler, Marcy, Kane); The Feinstein Institute for Medical Research, Manhasset, New York (Correll, D. G. Robinson, Marcy, Kane); Hofstra North Shore-LIJ School of Medicine, Hempstead, New York (Correll, D. G. Robinson, Kane); Albert Einstein College of Medicine, Bronx, New York (Correll, D. G. Robinson, Kane); State University of New York Downstate Medical Center, New York (Schooler); Geisel School of Medicine at Dartmouth, Dartmouth, New Hampshire (Brunette); Bureau of Behavioral Health, Department of Health and Human Services, Dartmouth, New Hampshire (Brunette); Department of Occupational Therapy, Center for Psychiatric Rehabilitation, Boston University, Boston, Massachusetts (Mueser); Department of Psychiatry, Center for Psychiatric Rehabilitation, Boston University, Boston, Massachusetts (Mueser); Department of Psychology, Center for Psychiatric Rehabilitation, Boston University, Boston, Massachusetts (Mueser); Department of Psychiatry and Epidemiology, Yale University, Princeton, New Jersey (Rosenheck); Department of Public Health, Yale University, Princeton, New Jersey (Rosenheck); Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada (Addington); Department of Social Medicine, University of North Carolina, Chapel Hill (Estroff); Nathan Kline Institute, Orangeburg, New York (J. Robinson); Department of Psychology, University of North Carolina, Chapel Hill (Penn); National Institute of Mental Health, Bethesda, Maryland (Azrin, Goldstein, Severe, Heinszen).

**Author Contributions:** Dr Correll had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Correll, D. G. Robinson, Schooler, Brunette, Mueser, Rosenheck, Marcy, Addington, Penn, Heinszen, Kane.

**Acquisition, analysis, or interpretation of data:**

Correll, D. G. Robinson, Schooler, Brunette, Marcy, Estroff, J. Robinson, Azrin, Goldstein, Severe.

**Drafting of the manuscript:** Correll, D. G. Robinson, Rosenheck.

**Critical revision of the manuscript for important intellectual content:** All authors.

**Statistical analysis:** Correll.

**Obtained funding:** Correll, D. G. Robinson, Brunette, Mueser, Estroff, Azrin, Heinszen, Kane.

**Administrative, technical, or material support:** D. G. Robinson, Schooler, Brunette, Marcy, J. Robinson, Penn, Severe.

**Study supervision:** Kane.

**Conflict of Interest Disclosures:** Dr Correll has been a consultant and/or advisor to or has received honoraria from Actelion, Alexza, American Academy of Child and Adolescent Psychiatry, Bristol-Myers Squibb, Cephalon, Eli Lilly and Co, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Lundbeck, Medavante, Medscape, Merck, National Institute of Mental Health, Janssen/Johnson & Johnson, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda and has received grant support from Bristol-Myers Squibb, Feinstein Institute for Medical Research, Janssen/Johnson & Johnson, National Institute of Mental Health, National Alliance for Research in Schizophrenia and Depression, Novo Nordisk A/S, and Otsuka. Dr D. G. Robinson has been a consultant to Asubio and Shire and has received grants from Bristol-Myers Squibb, Janssen, and Otsuka. Dr Schooler has been a consultant to Abbott, Amgen, Eli Lilly and Co, Janssen Psychiatry, Lundbeck, Merck, Nupathe, Pfizer, and Shire and has received grants from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, H. Lundbeck, Ortho-McNeil-Janssen, Neurocrine, Otsuka, and Pfizer. Dr Rosenheck has received research support from Janssen Pharmaceutica and Wyeth Pharmaceuticals; has been a consultant to Otsuka; and has provided expert testimony. Dr Addington has served as a consultant to Roche. Dr Kane has been a consultant and/or advisor to or has received honoraria from Alkermes, Amgen, Bristol-Myers Squibb, Eli Lilly and Co, Esai, Forest Laboratories, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Janssen, Jazz, Johnson & Johnson, Lundbeck, MedAvante, Merck, Novartis, Otsuka, Pierre Fabre, Proteus, Pfizer, Roche, Reviva, Sunovion, Takeda, Targacept, and Vanda and is a shareholder of MedAvante. No other disclosures were reported.

**Funding/Support:** This work was supported in part by grant HHSN-271-2009-00019C from the National Institute of Mental Health (Dr Kane) and by federal funds from the American Recovery and Reinvestment Act.

**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Previous Presentation:** This paper was presented in part at the 52nd Annual Meeting of the New Clinical Drug Evaluation Unit; May 30, 2013; Hollywood, Florida.

**Additional Contributions:** We thank the participating patients and their families, each of the participating 34 centers, and their personnel.

### REFERENCES

- Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. *J Clin Psychiatry*. 2007;68(6):899-907.
- Nielsen RE, Uggerby AS, Jensen SO, McGrath JJ. Increasing mortality gap for patients diagnosed with schizophrenia over the last three decades: a Danish nationwide study from 1980 to 2010. *Schizophr Res*. 2013;146(1-3):22-27.
- Suvisaari J, Partti K, Perälä J, et al. Mortality and its determinants in people with psychotic disorder. *Psychosom Med*. 2013;75(1):60-67.
- Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. *Prev Chronic Dis*. 2006;3(2):A42.
- Chang CK, Hayes RD, Perera G, et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. *PLoS ONE*. 2011;6(5):e19590.
- Druss BG, Zhao L, Von Esenwein S, Morrato EH, Marcus SC. Understanding excess mortality in persons with mental illness: 17-year follow up of a



- nationally representative US survey. *Med Care*. 2011;49(6):599-604.
7. Nordentoft M, Wahlbeck K, Hällgren J, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. *PLoS One*. 2013;8(1):e55176.
  8. Osby U, Correia N, Brandt L, Ekblom A, Sparén P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. *BMJ*. 2000;321(7259):483-484.
  9. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? *Arch Gen Psychiatry*. 2007;64(10):1123-1131.
  10. Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St Sauver J. Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. *Schizophr Res*. 2008;98(1-3):287-294.
  11. Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. *BMJ*. 2011;343:d5422.
  12. De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders, II: barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. *World Psychiatry*. 2011;10(2):138-151.
  13. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders, I: prevalence, impact of medications and disparities in health care. *World Psychiatry*. 2011;10(1):52-77.
  14. Mitchell AJ, Delafon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. *Psychol Med*. 2012;42(1):125-147.
  15. Mitchell AJ, Lord O. Do deficits in cardiac care influence high mortality rates in schizophrenia? a systematic review and pooled analysis. *J Psychopharmacol*. 2010;24(4)(suppl):69-80.
  16. Mitchell AJ, Lord O, Malone D. Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis. *Br J Psychiatry*. 2012;201(6):435-443.
  17. Lahti M, Tiihonen J, Wildgust H, et al. Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia. *Psychol Med*. 2012;42(11):2275-2285.
  18. De Hert M, Vancampfort D, Correll CU, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. *Br J Psychiatry*. 2011;199(2):99-105.
  19. Tsai KY, Lee CC, Chou YM, Su CY, Chou FH. The incidence and relative risk of stroke in patients with schizophrenia: a five-year follow-up study. *Schizophr Res*. 2012;138(1):41-47.
  20. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. *Trends Mol Med*. 2011;17(2):97-107.
  21. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. *Nat Rev Endocrinol*. 2012;8(2):114-126.
  22. Srihari VH, Phutane VH, Ozkan B, et al. Cardiovascular mortality in schizophrenia: defining a critical period for prevention. *Schizophr Res*. 2013;146(1-3):64-68.
  23. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. *JAMA*. 2009;302(16):1765-1773.
  24. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. *Arch Gen Psychiatry*. 2011;68(6):609-616.
  25. Ratliff JC, Palmese LB, Reutenauer EL, Srihari VH, Tek C. Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness. *Psychosomatics*. 2013;54(1):67-73.
  26. Tirosh A, Shai I, Afek A, et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. *N Engl J Med*. 2011;364(14):1315-1325.
  27. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. *J Clin Psychiatry*. 2010;71(9):1115-1124.
  28. Cullen BA, McGinty EE, Zhang Y, et al. Guideline-concordant antipsychotic use and mortality in schizophrenia. *Schizophr Bull*. 2013;39(5):1159-1168.
  29. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). *Lancet*. 2009;374(9690):620-627.
  30. Hoang U, Goldacre MJ, Stewart R. Avoidable mortality in people with schizophrenia or bipolar disorder in England. *Acta Psychiatr Scand*. 2013;127(3):195-201.
  31. First M, Spitzer R, Gibbon M, Williams J. *Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition*. New York: Biometrics Research, New York State Psychiatric Institute; 1998.
  32. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. *Br J Addict*. 1991;86(9):1119-1127.
  33. Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. *Int Rev Psychiatry*. 2008;20(2):195-201.
  34. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. *Arch Pediatr Adolesc Med*. 2003;157(8):821-827.
  35. Tóth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. *J Clin Lipidol*. 2012;6(4):325-330.
  36. American Diabetes Association. Standards of medical care in diabetes—2010. *Diabetes Care*. 2010;33(suppl 1):S11-S61.
  37. McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? *Am J Cardiol*. 2005;96(3):399-404.
  38. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. 1985;28(7):412-419.
  39. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003;289(19):2560-2572.
  40. Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*. 2005;112(17):2735-2752.
  41. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA*. 2002;287(3):356-359.
  42. Centers for Disease Control and Prevention. Vital signs: current cigarette smoking among adults aged  $\geq 18$  years with mental illness: United States, 2009-2011. *MMWR Morb Mortal Wkly Rep*. 2013;62(5):81-87.
  43. Keyes KM, Utz RL, Robinson W, Li G. What is a cohort effect? comparison of three statistical methods for modeling cohort effects in obesity prevalence in the United States, 1971-2006. *Soc Sci Med*. 2010;70(7):1100-1108.
  44. Crews DC, Plantinga LC, Miller ER III, et al; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Prevalence of chronic kidney disease in persons with undiagnosed or prehypertension in the United States. *Hypertension*. 2010;55(5):1102-1109.
  45. Heianza Y, Hara S, Arase Y, et al. HbA1c 5.7-6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. *Lancet*. 2011;378(9786):147-155.
  46. Fleischhacker WW, Siu CO, Bodén R, Pappadopoulos E, Karayal ON, Kahn RS; EUFEST Study Group. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. *Int J Neuropsychopharmacol*. 2013;16(5):987-995.
  47. Moreno C, Merchán-Naranjo J, Alvarez M, et al. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. *Bipolar Disord*. 2010;12(2):172-184.
  48. Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. *J Clin Psychiatry*. 2007;68(11):1733-1740.
  49. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. *Eur Psychiatry*. 2010;25(suppl 2):S12-S21.
  50. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine,

- and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. *Am J Psychiatry*. 2007;164(7):1050-1060.
51. Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. *J Clin Psychopharmacol*. 2008;28(6):601-607.
52. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. *Neuropsychopharmacology*. 2010;35(9):1997-2004.
53. Kahn RS, Fleischhacker WW, Boter H, et al; EUFEST Study Group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. *Lancet*. 2008;371(9618):1085-1097.
54. Buchanan RW, Kreyenbuhl J, Kelly DL, et al; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophr Bull*. 2010;36(1):71-93.
55. Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? a comparative meta-analysis of first episode, untreated and treated patients. *Schizophr Bull*. 2013;39(2):295-305.
56. McClave AK, McKnight-Eily LR, Davis SP, Dube SR. Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 National Health Interview Survey. *Am J Public Health*. 2010;100(12):2464-2472.
57. Manu P, Correll CU, Wampers M, et al. Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs. *Eur Neuropsychopharmacol*. 2013;23(3):205-211.
58. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. *Schizophr Res*. 2006;86(1-3):15-22.
59. Correll CU, Harris JL, Pantaleon Moya RA, Frederickson AM, Kane JM, Manu P. Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: missed targets and lost opportunities. *Schizophr Res*. 2007;92(1-3):103-107.
60. Correll CU, Druss BG, Lombardo I, et al. Findings of a US national cardiometabolic screening program among 10,084 psychiatric outpatients. *Psychiatr Serv*. 2010;61(9):892-898.
61. Centers for Disease Control and Prevention. Smoking-attributable mortality, years of potential life lost, and productivity losses: United States, 2000-2004. *MMWR Morb Mortal Wkly Rep*. 2008;57(45):1226-1228.
62. Mucha L, Stephenson J, Morandi N, Dirani R. Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking. *Gen Med*. 2006;3(4):279-291.
63. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ*. 2004;328(7455):1519.
64. Garrison RJ, Castelli WP. Weight and thirty-year mortality of men in the Framingham Study. *Ann Intern Med*. 1985;103(6, pt 2):1006-1009.
65. Stringhini S, Sabia S, Shipley M, et al. Association of socioeconomic position with health behaviors and mortality. *JAMA*. 2010;303(12):1159-1166.
66. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. *JAMA*. 2003;290(1):86-97.
67. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. *Arch Intern Med*. 2003;163(4):427-436.
68. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med*. 2005;353(12):1209-1223.
69. Fenelon A. Revisiting the Hispanic mortality advantage in the United States: the role of smoking. *Soc Sci Med*. 2013;82:1-9.
70. Daviglius ML, Talavera GA, Avilés-Santa ML, et al. Prevalence of major cardiovascular risk factors and cardiovascular diseases among Hispanic/Latino individuals of diverse backgrounds in the United States. *JAMA*. 2012;308(17):1775-1784.
71. Yu SS, Castillo DC, Courville AB, Sumner AE. The triglyceride paradox in people of African descent. *Metab Syndr Relat Disord*. 2012;10(2):77-82.
72. Li C, Ford ES, Meng YX, Mokdad AH, Reaven GM. Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity? *Cardiovasc Diabetol*. 2008;7:4.
73. Sumner AE, Zhou J, Doumatey A, et al. Low HDL-cholesterol with normal triglyceride levels is the most common lipid pattern in West Africans and African Americans with metabolic syndrome: implications for cardiovascular disease prevention. *CVD Prev Control*. 2010;5(3):75-80.
74. Lin SX, Carnethon M, Szklo M, Bertoni A. Racial/ethnic differences in the association of triglycerides with other metabolic syndrome components: the Multi-Ethnic Study of Atherosclerosis. *Metab Syndr Relat Disord*. 2011;9(1):35-40.
75. Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. *Ann Intern Med*. 2011;154(5):303-309.
76. Sentell TL, He G, Gregg EW, Schillinger D. Racial/ethnic variation in prevalence estimates for United States prediabetes under alternative 2010 American Diabetes Association criteria: 1988-2008. *Ethn Dis*. 2012;22(4):451-458.
77. Ziemer DC, Kolm P, Weintraub WS, et al. Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. *Ann Intern Med*. 2010;152(12):770-777.
78. Tsugawa Y, Mukamal KJ, Davis RB, Taylor WC, Wee CC. Should the hemoglobin A1c diagnostic cutoff differ between blacks and whites? a cross-sectional study. *Ann Intern Med*. 2012;157(3):153-159.
79. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. *Schizophr Res*. 2012;140(1-3):159-168.